RIVA-TENOFOVIR DIN 02515156
Health Canada record
| Active ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE 300 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AF07 TENOFOVIR DISOPROXIL |
| Original market date | 14-Jun-2021 |
| Current status date | 14-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Laboratoire Riva Inc. — licence 100179, currently licensed, last inspection rating C (2026-01-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TENOFOVIR DISOPROXIL FUMARATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02516276 | AG-TENOFOVIR | ANGITA PHARMA INC. | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02451980 | APO-TENOFOVIR | APOTEX INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02460173 | AURO-TENOFOVIR | AURO PHARMA INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02479087 | JAMP-TENOFOVIR | JAMP PHARMA CORPORATION | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02512939 | MINT-TENOFOVIR | MINT PHARMACEUTICALS INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02452634 | MYLAN-TENOFOVIR DISOPROXIL | MYLAN PHARMACEUTICALS ULC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02472511 | NAT-TENOFOVIR | NATCO PHARMA (CANADA) INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02453940 | PMS-TENOFOVIR | PHARMASCIENCE INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02523922 | TENOFOVIR | SIVEM PHARMACEUTICALS ULC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02512327 | TENOFOVIR | SANIS HEALTH INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02403889 | TEVA-TENOFOVIR | TEVA CANADA LIMITED | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02247128 | VIREAD | GILEAD SCIENCES CANADA INC | Tablet | TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25761 | 2021-04-28 | Abbreviated New Drug Submission (ANDS) | LICENSING AGREEMENT BETWEEN TWO COMPANIES |
International API supply for TENOFOVIR DISOPROXIL FUMARATE
26 active FDA Drug Master Files.
Request a quote for RIVA-TENOFOVIR